Cargando…

The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center

BACKGROUND: Bevacizumab combined with platinum-based chemotherapy has been approved in the first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) without driver genes, but this regimen for second-line or later-line treatment of non-squamous NSCLC remains to be further test...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long, Qianqian, Feng, Yu, Liu, Chang, Wu, Xianghua, Wang, Huijie, Yu, Hui, Zhao, Xinmin, Wang, Jialei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661884/ https://www.ncbi.nlm.nih.gov/pubmed/33209891 http://dx.doi.org/10.21037/atm-20-6327

Ejemplares similares

Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations
por: Liao, Jiatao, et al.
Publicado: (2021)

Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
por: Zhao, Xinmin, et al.
Publicado: (2017)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors
por: Zhao, Xinmin, et al.
Publicado: (2022)

Targeted therapy for cisplatin‐resistant lung cancer via aptamer‐guided nano‐zinc carriers containing USP14 siRNA
por: Zhao, Xinmin, et al.
Publicado: (2023)

Correction to: Targeted therapy for cisplatin‐resistant lung cancer via aptamer‐guided nano‐zinc carriers containing USP14 siRNA
por: Zhao, Xinmin, et al.
Publicado: (2023)

Exploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
por: Sun, Si, et al.
Publicado: (2017)

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
por: Hu, Zhihuang, et al.
Publicado: (2022)

Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
por: Wang, Jing, et al.
Publicado: (2023)

First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China
por: Qi, Fei, et al.
Publicado: (2019)

Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients
por: Tang, Ning, et al.
Publicado: (2016)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

A phase II study of anlotinib combined with etoposide and platinum‐based regimens in the first‐line treatment of extensive‐stage small cell lung cancer
por: Liu, Chang, et al.
Publicado: (2022)

PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials
por: Meng, Xiangjiao, et al.
Publicado: (2022)

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer
por: Reck, Martin, et al.
Publicado: (2020)

Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience
por: Wu, Pei-Ying, et al.
Publicado: (2020)

Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis
por: Xiao, Xian, et al.
Publicado: (2022)

Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor
por: Lin, Ying, et al.
Publicado: (2023)

Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis
por: Liu, Yi, et al.
Publicado: (2021)

Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis
por: Tang, Ning, et al.
Publicado: (2015)

Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer
por: Hamada, Shohei, et al.
Publicado: (2019)

Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia
por: Kristin, Erna, et al.
Publicado: (2021)

Facial nerve paresis in the course of masked mastoiditis as a revelator of GPA
por: Marszał, Joanna, et al.
Publicado: (2021)

KEYNOTE-407: new hope for the treatment of lung squamous cell carcinoma
por: Zhao, Xinmin, et al.
Publicado: (2020)

First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study
por: Wu, Yahua, et al.
Publicado: (2023)

Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials
por: Chen, Yan-xian, et al.
Publicado: (2014)

Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
por: Zhong, Hua, et al.
Publicado: (2023)

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) in patients with advanced non-squamous non-small cell lung cancer
por: Li, Cheryl S. W., et al.
Publicado: (2019)

Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR)
por: Udagawa, Hibiki, et al.
Publicado: (2021)

miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
por: Lindholm, Evita Maria, et al.
Publicado: (2019)

Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain
por: Lister, Johanna, et al.
Publicado: (2012)

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center
por: Liu, Chang, et al.
Publicado: (2019)

Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis
por: Chai, Yue, et al.
Publicado: (2022)

Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study
por: Qin, Shanshan, et al.
Publicado: (2019)

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
por: Cardona, Andrés Felipe, et al.
Publicado: (2016)

Hormone receptor expression correlates with EGFR gene mutation in lung cancer in patients with simultaneous primary breast cancer
por: Hu, Zhihuang, et al.
Publicado: (2020)

Prognostic significance and biological function of Lamina-associated polypeptide 2 in non-small-cell lung cancer
por: Liu, Chang, et al.
Publicado: (2019)

Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer
por: Hou, Junjie, et al.
Publicado: (2022)

Cutaneous metastasis reveling lung cancer
por: Elfatoiki, Fatima Zahra, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gkorgi1s7h1jv1vu1eg7gqesc6